LYZZ Capital β Full Portfolio
14 tracked investments Β· listed companies and verified rows first
A biopharmaceutical company developing oncology treatments including EGFR-targeting small molecule drugs for lung cancer with CNS penetration, and expanding into cell immunotherapy through licensed partnerships for NK cell and CAR-T therapies targeting solid tumors and hematologic malignancies.
BiotechDeep TechHealthtechMedical DevicesShanghai, CN
Xian-ping LU(Founder)in
Co-investorsLAVLilly Asia VenturesVertex Ventures China
Jumpcode Genomics develops CRISPRclean, a next-generation sequencing technology that removes abundant, uninformative sequences to improve sensitivity, lower costs, and simplify workflows for researchers.
AI & Machine LearningBiotechDeep TechHealthtechSan Diego, US
David Michael Salter(Executive Officer, Director)Mike Salter(CEO/President)inEugene Chen(Director)Keith Brown(Executive Officer, Director)Joel Rotroff(Director)
BoardCourt Turner(Director)
Co-investorsArboretum Ventures
MicroTech Medical provides medical information services in China, with operational headquarters in Hangzhou and a principal place of business in Hong Kong.
Digital HealthHardwareMedical DevicesHangzhou, CN
Co-investorsLAVLilly Asia VenturesQiming Venture Partners
Neurelis is a neuroscience-based biopharmaceutical company that develops treatments for people living with neurological conditions such as epilepsy.
BiotechHealthtechMedical DevicesEncinitas, US
Craig C. Chambliss(Executive Officer, Director)inCraig Chambliss(Founder)in
BoardDavid F. Hale(Director)Cam Garner(Director)Yong Zhang(Director)Kevin Li(Director)in
Co-investorsOrbiMed
BiotechPhoenix, US
Douglas Grant McFadden, Ph.D.(Director)Steven J. Potts, Ph.D.(President and Chief Executive Officer)Ting Xiao(Director)Jason Rushton(Director)Kanad Das, Ph.D.(Director)Michael G. Wood(Executive Officer)
Co-investorsB Capital GroupBoehringer Ingelheim Venture FundCity Hill VenturesDelos CapitalKorea Investment PartnersLumira Ventures+1 more
.jpeg){kind=logo}
QpexBio develops anti-infective drugs designed to overcome multidrug resistance, improving existing drug classes and discovering new ones for use in combination with known anti-infectives against drug-resistant bacteria.
BiotechHealthtechSan Diego, US
Michael N. Dudley(Executive Officer, Director)inTerry Gould(Director)Daniel Burgess(Director)
BoardCarol Gallagher(Director)inDouglas Reed(Director)inKevin Li(Director)in
Co-investorsHatteras Venture PartnersNew Enterprise Associates (NEA)Adams Street Partners
Allotera (formerly Wugen) develops allogeneic T-cell therapies.
BiotechHealthtechMedical DevicesSt. Louis, US
Ayman Kabakibi(Executive Officer)inCherry Thomas(Executive Officer)inKumar Srinivasan(Executive Officer, Director)inKeith Vendola(Executive Officer)Daniel M Kemp(Executive Officer, Director)Matthew Cooper(Executive Officer)
Co-investorsAisling CapitalAlpha Wave GlobalBioGenerator VenturesRiverVest Venture PartnersAbingworthFidelity Investments+1 more
Other
Tracked investments with no reachable website or further public details β typically companies that wound down, renamed, or were absorbed.
Allotera TherapeuticsWxyuannuoYun300Zhiyunyilu
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.